tirzepatide and bone loss Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes in obese mice via gut microbial-related metabolites Does Tirzepatide Cause Osteoporosis? Evidence

How to Protect Your Kidneys While Taking GLP-1 Drugs The good news is that the one real risk dehydration is also the most controllable

In clinical trial follow-ups, most participants began regaining weight within the first 3 months after stopping GLP-1 therapy

While the new indication for the drug means the TGA has satisfactory evidence of its benefits in regard to those particular conditions, it did not alter the cost of the drug

Coverage Differences by Plan Type Employer-Sponsored Plans Employer-sponsored plans are increasingly covering GLP-1s for weight management with a focus on outcomes-driven health benefits and overall employee well-being

Starting at lower doses minimizes the risk of severe gastrointestinal side effects and allows individuals to adapt to the peptide's effects on gastric emptying and appetite